Fennec Pharmaceuticals Inc. (FENC)
NASDAQ: FENC · Real-Time Price · USD
5.02
+0.38 (8.19%)
Nov 21, 2024, 1:12 PM EST - Market open

Company Description

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States.

The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients.

It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014.

Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals logo
Country United States
Founded 1996
IPO Date Jun 5, 2001
Industry Biotechnology
Sector Healthcare
Employees 29
CEO Rostislav Raykov

Contact Details

Address:
68 TW Alexander Drive, PO Box 13628
Research Triangle Park, North Carolina 27709
United States
Phone 919 636 4530
Website fennecpharma.com

Stock Details

Ticker Symbol FENC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001211583
CUSIP Number 31447P100
ISIN Number CA31447P1009
SIC Code 2836

Key Executives

Name Position
Rostislav Raykov Chief Executive Officer and Director
Robert C. Andrade Chief Financial Officer
Terry Evans Chief Commercial Officer
Dr. Pierre S. Sayad M.S., Ph.D. Chief Medical Officer
Christiana Cioffi M.B.A. Chief Strategy Officer
Mark Gowland Controller
Lei Fang President of Pharstat Inc

Latest SEC Filings

Date Type Title
Nov 14, 2024 SCHEDULE 13G/A Filing
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 10-Q Quarterly Report
Nov 4, 2024 144 Filing
Oct 30, 2024 8-K Current Report
Oct 1, 2024 144 Filing
Sep 5, 2024 144 Filing
Sep 4, 2024 144 Filing
Aug 13, 2024 10-Q Quarterly Report
Aug 7, 2024 8-K Current Report